Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength? [Yahoo! Finance]
Dianthus Therapeutics, Inc. (DNTH)
Company Research
Source: Yahoo! Finance
The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 43.8% gain over the past four weeks. This rise in share price is attributed to positive investor expectations around its pipeline. The stock has been surging over the past month after the company announced an early “GO” decision in the late-stage CAPTIVATE study evaluating claseprubart for a rare autoimmune disease called chronic inflammatory demyelinating polyneuropathy (CIDP). This decision came ahead of schedule as the company hit its interim responder goals. Dianthus' shares received an additional boost last week after the FDA agreed to several proposed changes related to clinical development of claseprubart, including updates to screening criteria, routine lab work and autoimmune safety monitoring. These changes apply to all ongoing and future studies. This company is expected to post quarterly loss of $1.17 per share in its upcoming report, which r
Show less
Read more
Impact Snapshot
Event Time:
DNTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNTH alerts
High impacting Dianthus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DNTH
News
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Dianthus Therapeutics CFO Sells $9.5 Million in Stock [Yahoo! Finance]Yahoo! Finance
- How Investors May Respond To Dianthus Therapeutics (DNTH) Early “GO” Decision And FDA Backing For Claseprubart [Yahoo! Finance]Yahoo! Finance
- Dianthus Therapeutics (DNTH) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $135.00 price target on the stock.MarketBeat
- Wedbush Keeps Outperform on Dianthus Therapeutics, Inc. (DNTH), Highlights Potential of Claseprubart in CIDP [Yahoo! Finance]Yahoo! Finance
DNTH
Earnings
- 3/9/26 - Miss
DNTH
Sec Filings
- 4/1/26 - Form 4
- 4/1/26 - Form 4
- 3/31/26 - Form 144
- DNTH's page on the SEC website